ロード中...
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
BACKGROUND: Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and health implications for patients. Limited data is...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6544996/ https://ncbi.nlm.nih.gov/pubmed/31151428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5729-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|